The platelet-derived growth factor receptor as a therapeutic target

Current Oncology Reports

Volumn 9, Issue 2, 2007, Pages 89-95

  Lewis, Nancy L ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; CARBOPLATIN; CP 868596; DASATINIB; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; KRN 951; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NILOTINIB; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DRUG ERUPTION; DRUG POTENTIATION; DRUG TARGETING; DYSGEUSIA; FATIGUE; FEVER; FLUID RETENTION; HAIR COLOR; HEADACHE; HUMAN; HYPERTENSION; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PLEURA EFFUSION; REVIEW; SIDE EFFECT; STROMA CELL; THROMBOCYTOPENIA; THYROID DISEASE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 33847355253     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0003-6     Document Type: Review

References (48)

1. Bhowmick NA, Moses HL: Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
2. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71.
3. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
4. Li H, Fredriksson L, Li X, Eriksson U: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003, 22:1501-1510.
5. Wang D, Huang HJ, Kazlauskas A, Cavenee WK: Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999, 59:1464-1472.
6. Hellstrom M, Kalen M, Lindahl P, et al.: Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
7. Uutela M, Lauren J, Bergsten E, et al.: Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFC genes. Circulation 2001, 103:2242-2247.
8. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
9. George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001, 28(5 Suppl 17):27-33.
10. Tallquist M, Kazlauskas A: PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004, 15:205-213.
11. Pietras K, Sjoblom T, Rubin K, et al.: PDGF receptors as cancer drug targets. Cancer Cell 2003, 3:439-443.
12. Betsholtz C Karlsson L, Lindahl P: Developmental roles of platelet-derived growth factors. Bioessays 2001, 23:494-507.
13. Rodt SA, Ahlén K, Berg A, et al.: A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 1996, 495(Pt 1):193-200.
14. Heuchel R, Berg A, Tallquist M, et al.: Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. Proc Natl Acad Sci U S A 1999, 96:11410-11415.
15. Ostman A, Heldin CH: Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001, 80:1-38.
16. von Tell D, Armulik A, Betsholtz C: Pericytes and vascular stability. Exp Cell Res 2006, 312:623-629.
17. Jain RK: Delivery of molecular medicine to solid tumors. Science 1996, 271:1079-1080.
18. Pietras K, Ostman A, Sjoquist M, et al.: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61:2929-2934.
19. Pietras K, Rubin K, Sjoblom T, et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476-5484.
20. Pietras K, Stumm M, Hubert M, et al.: STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003, 9:3779-3787.
21. Laird AD, Christensen JG, Li G, et al.: SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002, 16:681-690.
22. Bergers G, Song S, Meyer-Morse N, et al.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
23. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
24. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825.
25. Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
26. Rubin BP, Singer S, Tsao C, et al.: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-8121.
27. Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
28. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
29. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
30. Corless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23:5357-5364.
31. Buchdunger E, Cioffi CL, Law N, et al.: Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
32. Simon MP, Pedeutour F, Sirvent N, et al.: Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997, 15:95-98.
33. Shimizu A, O'Brien KP, Sjoblom T, et al.: The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999, 59:3719-3723.
34. Maki RG, Awan RA, Dixon RH, et al.: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100:623-626.
35. Rubin BP, Schuetze SM, Eary JF, et al.: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591.
36. Jousset C, Carron C, Boureux A, et al.: A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. Embo J 1997, 16:69-82.
37. Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
38. Chen Z Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006, 69:1527-1533.
39. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
40. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
41. Motzer RJ, Bander NH, Nanus DM: Renat-cell carcinoma. N Engl J Med 1996, 335:865-875.
42. Motzer RJ, Michaelson MD, Redman BG, et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
43. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
44. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
45. Ratain MJ, Eisen T, Stadler WM, et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
46. Lin B, Podar K, Gupta D, et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002, 62:5019-5026.
47. Rini B, Rixe O, Bukowski R, et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) [abstract]. J Clin Oncol Proc ASCO 2005, 26:4509.
48. Kim S, Rosen LS, Cohen EE, et al.: A Phase II study of axitinib (AG-013736), a potent inhibitor of BEGFRs, in patients with advanced thyroid cancer [abstract]. J Clin Oncol Proc ASCO 2006, 27:5539.